Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Cynthia Gargano"'
Autor:
Allan Lawrie, Kelly Chin, Yiu‐Lian Fong, Cynthia Gargano, Xavier Gitton, Cheng He, David G. Kiely, Li Zhou, Lihan Zhou, Bradley A. Maron, Debbie Quinn, Stephan Rosenkranz, Dimitri Stamatiadis, Mark Toshner, Martin R. Wilkins, Luke Howard, Ioana R. Preston
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 2, Pp n/a-n/a (2024)
Abstract A blood test identifying patients at increased risk of pulmonary hypertension (PH) could streamline the investigative pathway. The prospective, multicenter CIPHER study aimed to develop a microRNA‐based signature for detecting PH in breath
Externí odkaz:
https://doaj.org/article/b8ab45400a204fd294105f2eb5f0f631
Autor:
Ioana R. Preston, Stephan Rosenkranz, Dimitri Stamatiadis, Deborah A. Quinn, Cynthia Gargano, Yiu-Lian Fong, Luke Howard, Kelly Chin, Martin R. Wilkins, Mark Toshner, Bradley A. Maron, David G. Kiely
Publikováno v:
Chest. 158:A2191-A2193
Autor:
Cynthia Gargano, Gopi Shankar, Zhenhua Xu, Omoniyi J. Adedokun, Elizabeth C. Hsia, Jocelyn H. Leu
Publikováno v:
Rheumatology. 58:441-446
Objective Golimumab immunogenicity was extensively studied during clinical development. As anti-drug antibody (ADA) detection with the standard bridging EIA (original-EIA) can yield false-negative results or underestimate ADA incidence and titres due
Autor:
Martin R. Wilkins, Yiu-Lian Fong, Stephan Rosenkranz, Kelly Chin, Ioana R. Preston, Bradley A. Maron, Dimitri Stamatiadis, David G. Kiely, Cynthia Gargano, Luke Howard, Mark Toshner, Deborah A. Quinn
Publikováno v:
Pulmonary hypertension.
Autor:
Arie Struyk, Cynthia Gargano, Junshui Ma, David Mayleben, S. Aubrey Stoch, Vladimir Svetnik, Melissa Drexel
Publikováno v:
European Neuropsychopharmacology. 26:1649-1656
The objective of this study was to evaluate sleep electrophysiology in healthy subjects after bedtime administration of therapeutic doses of two insomnia treatments - the orexin receptor antagonist suvorexant or the GABAergic agonist zolpidem. Eighte
Autor:
George R Gunn, Zhenhua Xu, Omoniyi J. Adedokun, Cynthia Gargano, Jocelyn H. Leu, Paul Rutgeerts, William J. Sandborn, Gopi Shankar
Publikováno v:
Inflammatory bowel diseases. 25(9)
Background Antidrug antibody (ADA) detection with standard bridging enzyme immunoassays (EIA) can yield false-negative results or underestimate titers through drug interference. A more sensitive assay was needed to determine clinical impact of antigo
Autor:
Ingeborg Heirman, Arthur A. Simen, Kim Bleys, Jang-Ho Cha, Chan R. Beals, T Laethem, Cynthia Gargano, Arie Struyk, Aubrey Stoch, Melissa Drexel, Gary G. Kay, Thomas Hochadel, Lien Gheyle, An Bautmans
Publikováno v:
Therapeutic Advances in Drug Safety. 6:86-97
Objectives: We sought to validate Cognitive Research Corporation’s Driving Simulator (CRCDS Mini-Sim) for studies of drug safety with respect to driving ability. Methods: A total of 30 healthy subjects were randomized to receive placebo or 7.5 mg z
Autor:
Erik T. te Beek, Jacqueline B. McCrea, Joop M. A. van Gerven, Kristien Van Dyck, Kevin J. Petty, Anup K. Majumdar, Cynthia Gargano, Erica S. Klaassen, Gail Murphy, Diana Selverian, Daniel Tatosian
Publikováno v:
The Journal of Clinical Pharmacology. 53:846-856
Recent interest in NK1 receptor antagonists has focused on a potential role in the treatment of drug addiction and substance abuse. In the present study, the potential for interactions between the NK1 receptor antagonist aprepitant and alcohol, given
Autor:
M. Gail Murphy, Howard E. Greenberg, Anup K. Majumdar, Walter K. Kraft, Matthew P. Braun, Dennis C. Dean, Keith Gottesdiener, Kevin J. Petty, S. Aubrey Stoch, Margaret Fedgchin, Jack Valentine, Deborah Panebianco, Cynthia Gargano, Edward Pequignot
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:1313-1321
Because glucocorticoids and the neurokinin-1 receptor antagonist aprepitant influence CYP3A4 activity, this study assessed whether aprepitant added to a 5-HT3 antagonist and glucocorticoid would affect CYP3A4 induction. In this double-blind, 2-period
Autor:
Thomas E. Bradstreet, Craig R. Shadle, Robert A. Blum, Yih Lee, Judith K. Evans, Anup K. Majumdar, Cynthia Gargano, Kevin J. Petty
Publikováno v:
The Journal of Clinical Pharmacology. 44:215-223
The NK(1) receptor antagonist aprepitant (EMEND(R)), developed for use in combination with a 5HT(3) receptor antagonist and a corticosteroid to prevent highly emetogenic chemotherapy-induced nausea and vomiting (CINV), has been shown to have a modera